| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/21/2002 | DE10026678C1 Transdermal patch for delivery of non-steroidal antiinflammatory agent, containing e.g. alkyl-pyrrolidone, metal salt, surfactant and polymers, provides good drug release and absorption properties |
| 03/21/2002 | CA2422829A1 Patch comprising diclofenac |
| 03/21/2002 | CA2422828A1 Novel tumor-associated marker |
| 03/21/2002 | CA2422603A1 Vectors for molecule delivery to cd11b expressing cells |
| 03/21/2002 | CA2422575A1 Composition comprising immunogenic microparticles |
| 03/21/2002 | CA2422278A1 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421966A1 Remedies for ischemic diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2416563A1 Pharmaceutical composition having specific water activity |
| 03/21/2002 | CA2406446A1 Diphosphonate solutions |
| 03/21/2002 | CA2391162A1 Novel topical oestroprogestational compositions with systemic effect |
| 03/20/2002 | EP1188448A2 Heparin-binding growth factors for gene therapy and anterior eye disorders |
| 03/20/2002 | EP1188446A1 Proteinaceous vectors for molecule delivery to CD11b expressing cells |
| 03/20/2002 | EP1188445A1 Drug composition containing lecithin-modified superoxide dismutase |
| 03/20/2002 | EP1188444A1 FSH and FSH variant formulations, products and methods |
| 03/20/2002 | EP1188440A1 Medicinal composition for oral administration |
| 03/20/2002 | EP1188057A2 Incorporation and appliations of biomolecular interactions within a carrier |
| 03/20/2002 | EP1187929A2 Novel liposomal vector complexes and their use in gene therapy |
| 03/20/2002 | EP1187807A1 Bipolar lipids and their use for the delivery of bioactive substances |
| 03/20/2002 | EP1187806A2 Spermine:peptide-based surfactant compounds |
| 03/20/2002 | EP1187803A1 Amorphous nitric esters and their pharmaceutical compositions |
| 03/20/2002 | EP1187639A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| 03/20/2002 | EP1187637A2 Alpha or beta emitters attached to fragments in radioimmunotherapy |
| 03/20/2002 | EP1187636A1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 03/20/2002 | EP1187622A1 Method of sterilizing |
| 03/20/2002 | EP1187601A1 Novel preparation and administration form comprising an acid-labile active compound |
| 03/20/2002 | EP1187600A1 Method for enhancing stable cellular creatine concentration |
| 03/20/2002 | EP1187539A1 Method and composition for masking mineral taste |
| 03/20/2002 | EP1143796A4 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 03/20/2002 | EP1077687B1 Multiparticulate pharmaceutical form with programmed and timed release and preparation method |
| 03/20/2002 | EP1017696B1 Acidic addition salts of morphine alkaloids and the application thereof |
| 03/20/2002 | EP1009396B1 Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin |
| 03/20/2002 | EP0986568B1 Novel class of nucleic acid cationic transfecting agents |
| 03/20/2002 | EP0957906B1 Local anesthetic for external use |
| 03/20/2002 | EP0948340B1 Biologically active substances, method for obtaining and compositions containing them |
| 03/20/2002 | EP0786986B1 Use of an unsaturated fatty alcohol |
| 03/20/2002 | EP0785796B1 A pharmaceutical formulation comprising a growth hormone and isoleucine |
| 03/20/2002 | EP0778778B1 Probiotic compositions |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | CN1341124A Anti-CD3 immunotoxins and therapeutic use thereof |
| 03/20/2002 | CN1341122A Covalently bridged insulin dimers |
| 03/20/2002 | CN1341029A Use of an OmpA enterobacteriumprotein associated with the ELAGIGILTV peptide for treating melanomas |
| 03/20/2002 | CN1341022A Pharmaceutical composition containing porton pump inhibitors |
| 03/20/2002 | CN1341016A Effervescent laxatives |
| 03/20/2002 | CN1341015A Sheet-form adhesive preparation |
| 03/20/2002 | CN1081071C Compounding method of bone morphogenesis protein to calcined bone |
| 03/20/2002 | CN1081038C Beta-glucan products and extraction process from cereals thereof |
| 03/20/2002 | CN1081030C External preparation containing tranilast and process for producing the same |
| 03/20/2002 | CN1081029C Sustained-release metal valproate tablets |
| 03/20/2002 | CN1081028C Patch for external use |
| 03/19/2002 | US6359126 Antibodies to αvβ3 integrin |
| 03/19/2002 | US6359054 For gene therapy |
| 03/19/2002 | US6359016 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 03/19/2002 | US6359014 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 03/19/2002 | US6359011 Denaturants for sympathomimetic amine salts |
| 03/19/2002 | US6359006 Antiischemic agents; anticancer agents |
| 03/19/2002 | US6358989 Therapeutic inhibitor of vascular smooth muscle cells |
| 03/19/2002 | US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 03/19/2002 | US6358935 Preserved cyclodextrin-containing compositions |
| 03/19/2002 | US6358930 Treatment of C. difficile toxin B associated conditions |
| 03/19/2002 | US6358924 GLP-1 formulations |
| 03/19/2002 | US6358919 Polymer compounds comprising glycosphingosine |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358710 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 |
| 03/19/2002 | US6358697 Intracellular pharmaceutical targeting |
| 03/19/2002 | US6358533 Pharmaceutical excipient having improved compressibility |
| 03/19/2002 | US6358530 Powdered pharmaceutical formulations having improved dispersibility |
| 03/19/2002 | US6358524 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |
| 03/19/2002 | US6358523 Macromolecule-lipid complexes and methods for making and regulating |
| 03/19/2002 | US6358522 For reducing anal leakage of oil in a patient to whom orlistat is being administered |
| 03/19/2002 | US6358514 Combination of a retinoid with a histidine derivative |
| 03/19/2002 | US6358490 Biotin conjugated to therapeutic or diagnostic radionuclides or other active agents such as chemotherapeutic drugs, antitumor agents such as cytokines enhances active agent localization |
| 03/19/2002 | US6358443 Directing microdroplets into freezing section containing a liquefied gas; contacting frozen microdroplets in extraction section with liquid non-solvent to extract solvent into non-solvent to form microparticles |
| 03/19/2002 | CA2319966A1 Improved dextran-hemoglobin conjugate as potential blood substitute |
| 03/19/2002 | CA2231886C Copolymeric micelle drug composition and method for the preparation thereof |
| 03/19/2002 | CA2106975C Process for conditioning of water-soluble substances |
| 03/19/2002 | CA2078885C Pharmaceutical compositions containing amethocaine |
| 03/19/2002 | CA2067733C Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure |
| 03/19/2002 | CA2034569C Oral pharmaceutical forms of pimobendan |
| 03/19/2002 | CA1341349C Functionalized polyamine chelants and rhodium complexes thereof for conjugation to antibodies |
| 03/18/2002 | CA2319928A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| 03/17/2002 | WO2002017957A1 Solution preparations stabilized over long time |
| 03/14/2002 | WO2002021134A2 Methods of diagnosing breast cancer and screening for modulators |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020762A2 Tnf receptor-like molecules and uses thereof |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020715A2 Peptide conjugated anti-cancer prodrugs |
| 03/14/2002 | WO2002020663A2 Degradable polyacetal polymers |
| 03/14/2002 | WO2002020649A1 Composition for soluble films with a new hydrolyzed polysaccharide |
| 03/14/2002 | WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | WO2002020610A2 Conformationally constrained labeled peptides for imaging and therapy |
| 03/14/2002 | WO2002020558A2 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof |
| 03/14/2002 | WO2002020510A1 Acid-sensitive compounds, preparation and uses thereof |
| 03/14/2002 | WO2002020508A1 Polyoxyethylene-polyoxypropylene vitamin e and process for preparation thereof |
| 03/14/2002 | WO2002020466A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |